2 CHAPTER 2 44 23. Pavelek Z,Soucek O,Krejsek J,et al.The role of the immune system and the biomarker CD3 + CD4 + CD45RA-CD62L- in the pathophysiology of migraine. Sci Rep. 2020;10(1):12277. 24. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128(3):209-214. 25. Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191-1196. 26. Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;35(4):310-316. 27. Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM.Vascular risk factors,endothelial function, and carotid thickness in patients with migraine: relationship to atherosclerosis. J Stroke Cerebrovasc Dis. 2010;19(2):92-103. 28. Kurth T, Ridker PM, Buring JE. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2008;28(1):49-56. 29. Tietjen GE, Khubchandani J, Herial N, et al. Migraine and vascular disease biomarkers: A population-based case-control study. Cephalalgia. 2018;38(3):511-518. 30. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. 31. Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366-373. 32. Ramon C, Cernuda-Morollon E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol. 2017;30(3):281-286. 33. Greco R, De Icco R, Demartini C, et al. Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain. 2020;21(1):122. 34. Hagen K, Stovner LJ, Zwart JA. High sensitivity C-reactive protein and risk of migraine in a 11-year follow-up with data from the NordTrondelag health surveys 2006-2008 and 20172019. J Headache Pain. 2020;21(1):67. 35. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-1083. 36. Stam AH, de Vries B, Janssens AC, et al. Shared genetic factors in migraine and depression: evidence from a genetic isolate. Neurology. 2010;74(4):288-294. 37. Aulchenko YS, Heutink P, Mackay I, et al. Linkage disequilibrium in young genetically isolated Dutch population. Eur J Hum Genet. 2004;12(7):527-534. 38. Sleegers K, de Koning I, Aulchenko YS, et al. Cerebrovascular risk factors do not contribute to genetic variance of cognitive function: the ERF study. Neurobiol Aging. 2007;28(5):735-741. 39. Headache Classification Subcommittee of the International Headache S. The International Classification of Headache Disorders: 2nd edition. Cephalalgia : an international journal of headache. 2004;24 Suppl 1:9-160. 40. Vaarhorst AA, Verhoeven A, Weller CM, et al. A metabolomic profile is associated with the risk of incident coronary heart disease. Am Heart J. 2014;168(1):45-52 e7. 41. Findeisen M, Brand T, Berger S. A H-1-NMR thermometer suitable for cryoprobes. Magn Reson Chem. 2007;45(2):175-178. 42. Wu PSC, Otting G. Rapid pulse length determination in high-resolution NMR. J Magn Reson. 2005;176(1):115-119. 43. Price WS. Water Signal Suppression in NMR Spectroscopy. Annu Rep NMR Spectrosc. 1999;38:289-354. 44. Aue WP, Karhan J, Ernst RR. Homonuclear Broad-Band Decoupling and 2-Dimensional J-Resolved Nmr-Spectroscopy. J Chem Phys. 1976;64(10):4226-4227. 45. Meiboom S, Gill D. Modified Spin-Echo Method for Measuring Nuclear Relaxation Times. Rev Sci Instrum. 1958;29(8):688-691.
RkJQdWJsaXNoZXIy MTk4NDMw